XENON PHARMACEUTICALS INC. AND TAKEDA PHARMACEUTICAL CO. LTD. ANNOUNCE AGREEMENT TO DEVELOP AND COMMERCIALIZE XEN401 FOR PAIN IN JAPAN AND CERTAIN ASIAN COUNTRIES

Xenon Pharmaceuticals Inc. (Xenon) and Takeda Pharmaceutical Company Limited (Takeda) announced that the companies have entered into an exclusive agreement to develop and commercialize oral formulations of Xenon's lead product for pain, XEN401, in Japan and certain Asian countries. XEN401 is currently in preclinical development. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=31854&full=1)